Takeda ending discovery, preclinical work in AAV gene therapy, rare hematology

Kyle LaHucik

Associate Editor

Takeda told employees recently it is ending discovery and preclinical work in AAV gene therapy as well as research and preclinical work on rare hematology, a spokesperson confirmed in an emailed statement to Endpoints News.

The move will not impact the existing clinical development pipeline or commercial products, the spokesperson said, noting the number of employees impacted is yet to be determined as they might be redeployed to other R&D areas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Takeda ending discovery, preclinical work in AAV gene therapy, rare hematology

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

Take­da end­ing dis­cov­ery, pre­clin­i­cal work in AAV gene ther­a­py, rare hema­tol­ogy

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

Takeda ending discovery, preclinical work in AAV gene therapy, rare hematology

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...